BeOne Medicines Schedules 26 Aug 2026 Audit Committee Meeting to Approve 1H26 Results Aligned with Earlier U.S. Filing

Bulletin Express08-14

BeOne Medicines Ltd. (BeOne Medicines) has announced that its board audit committee will convene on 26 August 2026 (Hong Kong time) to consider and approve the interim results for the six months ended 30 June 2026 and authorise their release under Hong Kong Listing Rules.

The forthcoming disclosure will mirror the interim results previously released on 5 August 2026 in the company’s Form 10-Q filed with the U.S. Securities and Exchange Commission. The Hong Kong version will incorporate additional information mandated by local listing regulations, including a reconciliation from U.S. GAAP to IFRS.

Corporate governance remains unchanged. The board comprises Chairman and Executive Director Mr. John V. Oyler; Non-executive Directors Dr. Felix J. Baker and Dr. Xiaodong Wang; and Independent Non-executive Directors Dr. Olivier Brandicourt, Dr. Margaret Han Dugan, Mr. Anthony C. Hooper, Ms. Elizabeth F. Mooney, Dr. Alessandro Riva, Dr. Charles L. Sawyers and Ms. Shalini Sharp.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1193188148?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-14 17:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1193188148","market":"hk","top_or_hot":-1,"title":"BeOne Medicines Schedules 26 Aug 2026 Audit Committee Meeting to Approve 1H26 Results Aligned with Earlier U.S. Filing","media":"Bulletin Express","content":"<p>BeOne Medicines Ltd. (BeOne Medicines) has announced that its board audit committee will convene on 26 August 2026 (Hong Kong time) to consider and approve the interim results for the six months ended 30 June 2026 and authorise their release under Hong Kong Listing Rules.</p>\n<p>The forthcoming disclosure will mirror the interim results previously released on 5 August 2026 in the company’s Form 10-Q filed with the U.S. Securities and Exchange Commission. The Hong Kong version will incorporate additional information mandated by local listing regulations, including a reconciliation from U.S. GAAP to IFRS.</p>\n<p>Corporate governance remains unchanged. The board comprises Chairman and Executive Director Mr. John V. Oyler; Non-executive Directors Dr. Felix J. Baker and Dr. Xiaodong Wang; and Independent Non-executive Directors Dr. Olivier Brandicourt, Dr. Margaret Han Dugan, Mr. Anthony C. Hooper, Ms. Elizabeth F. Mooney, Dr. Alessandro Riva, Dr. Charles L. Sawyers and Ms. Shalini Sharp.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeOne Medicines Schedules 26 Aug 2026 Audit Committee Meeting to Approve 1H26 Results Aligned with Earlier U.S. Filing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeOne Medicines Schedules 26 Aug 2026 Audit Committee Meeting to Approve 1H26 Results Aligned with Earlier U.S. Filing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-14 17:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BeOne Medicines Ltd. (BeOne Medicines) has announced that its board audit committee will convene on 26 August 2026 (Hong Kong time) to consider and approve the interim results for the six months ended 30 June 2026 and authorise their release under Hong Kong Listing Rules.</p>\n<p>The forthcoming disclosure will mirror the interim results previously released on 5 August 2026 in the company’s Form 10-Q filed with the U.S. Securities and Exchange Commission. The Hong Kong version will incorporate additional information mandated by local listing regulations, including a reconciliation from U.S. GAAP to IFRS.</p>\n<p>Corporate governance remains unchanged. The board comprises Chairman and Executive Director Mr. John V. Oyler; Non-executive Directors Dr. Felix J. Baker and Dr. Xiaodong Wang; and Independent Non-executive Directors Dr. Olivier Brandicourt, Dr. Margaret Han Dugan, Mr. Anthony C. Hooper, Ms. Elizabeth F. Mooney, Dr. Alessandro Riva, Dr. Charles L. Sawyers and Ms. Shalini Sharp.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1193188148","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1193188148","pubTimestamp":1786699592,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"BeOne Medicines Ltd. (BeOne Medicines) has announced that its board audit committee will convene on 26 August 2026 (Hong Kong time) to consider and approve the interim results for the six months...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州"},"translate_title":"BeOne Medicines 计划于 2026 年 8 月 26 日召开审计委员会会议，批准 26 年上半年业绩，与之前的美国文件一致","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"BeOne Medicines Ltd. (BeOne Medicines) has announced that its board audit committee will convene on 26 August 2026 (Hong Kong time) to consider and approve the interim results for the six months ended 30 June 2026 and authorise their release under Hong Kong Listing Rules.\nThe forthcoming disclosure will mirror the interim results previously released on 5 August 2026 in the company’s Form 10-Q filed with the U.S. Securities and Exchange Commission. The Hong Kong version will incorporate additional information mandated by local listing regulations, including a reconciliation from U.S. GAAP to IFRS.\nCorporate governance remains unchanged. The board comprises Chairman and Executive Director Mr. John V. Oyler; Non-executive Directors Dr. Felix J. Baker and Dr. Xiaodong Wang; and Independent Non-executive Directors Dr. Olivier Brandicourt, Dr. Margaret Han Dugan, Mr. Anthony C. Hooper, Ms. Elizabeth F. Mooney, Dr. Alessandro Riva, Dr. Charles L. Sawyers and Ms. Shalini Sharp.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1193188148","isCrawlerRequest":true}